Phase 2 Adjuvant Clinical Trials
68 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 68 trials
Recruiting
Phase 2
Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer
ctDNAColorectal Cancer (CRC)Adjuvant Chemotherapy
Fudan University80 enrolled1 locationNCT07562659
Recruiting
Phase 2
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
Neoadjuvant TreatmentThyroid Cancer
M.D. Anderson Cancer Center45 enrolled1 locationNCT06959511
Recruiting
Phase 2
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Primary Peritoneal CancerFallopian Tube CancerNeoadjuvant+1 more
AbbVie140 enrolled57 locationsNCT06890338
Recruiting
Phase 2
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
Minimal Residual DiseaseAdjuvant Chemotherapy
M.D. Anderson Cancer Center20 enrolled1 locationNCT07136077
Recruiting
Phase 2
CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer
Neoadjuvant TherapyLocally Advanced Rectal Cancer
Fudan University192 enrolled1 locationNCT06281405
Recruiting
Phase 2
Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
Neoadjuvant TherapyKRAS G12C MutationResectable NSCLC+1 more
Jianxing He30 enrolled3 locationsNCT07492342
Recruiting
Phase 2
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
Neoadjuvant TherapyImmunotherapyTislelizumab+3 more
Seventh Medical Center of PLA General Hospital50 enrolled1 locationNCT07458529
Recruiting
Phase 2
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8+26 more
M.D. Anderson Cancer Center50 enrolled1 locationNCT04771520
Recruiting
Phase 2
Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients
Breast CancerEarly Stage Breast CancerAdjuvant Treatment
Dartmouth-Hitchcock Medical Center62 enrolled1 locationNCT07071038
Recruiting
Phase 2
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Neoadjuvant TherapyClear Cell Renal Cell CarcinomaIparomlimab and Tuvonralimab
Sun Yat-sen University25 enrolled1 locationNCT07389629
Recruiting
Phase 1Phase 2
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
Esophageal Squamous Cell CarcinomaNeoadjuvantIvonescimab
Tang-Du Hospital45 enrolled1 locationNCT07385001
Recruiting
Phase 2
Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma
ESCCPathological Complete ResponseTotal Neoadjuvant Treatment
National Taiwan University Hospital50 enrolled1 locationNCT06764355
Recruiting
Phase 2
Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
Hepatocellular CarcinomaNeoadjuvant TherapySintilimab+1 more
Sun Yat-sen University37 enrolled1 locationNCT07324824
Recruiting
Phase 2
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
MRDNSCLC (Non-small Cell Lung Cancer)II-IIIB Stages+1 more
Guangdong Association of Clinical Trials115 enrolled2 locationsNCT07120698
Recruiting
Phase 2
Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC)
Neoadjuvant Immunotherapy
Tianjin Medical University Second Hospital21 enrolled1 locationNCT05837806
Recruiting
Phase 2
Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Single-Arm, Phase II Trial
Colon CancerRadiation TherapyNeoadjuvant Therapies+1 more
Sixth Affiliated Hospital, Sun Yat-sen University38 enrolled1 locationNCT07279077
Recruiting
Phase 2
Node-Sparing Hypofractionated Radiotherapy Plus Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Randomized, Phase II Trial
RadiotherapyNeoadjuvant TherapiesImmune Checkpoint Therapy
Sixth Affiliated Hospital, Sun Yat-sen University52 enrolled1 locationNCT07230639
Recruiting
Phase 2
QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II Trial
Neoadjuvant Treatment for Locally Advanced Cervical Cancer
Affiliated Cancer Hospital & Institute of Guangzhou Medical University50 enrolled1 locationNCT07286253
Recruiting
Phase 2
Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Neoadjuvant TherapyEsophageal Squamous Cell Carcinoma
Shanghai Zhongshan Hospital26 enrolled1 locationNCT07266493
Recruiting
Phase 2
Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell CarcinomaNeoadjuvant Treatment
Second Affiliated Hospital, School of Medicine, Zhejiang University35 enrolled1 locationNCT06576973